News Image

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Provided By GlobeNewswire

Last update: Mar 13, 2025

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples

Read more at globenewswire.com

MAINZ BIOMED NV

NASDAQ:MYNZ (4/25/2025, 6:30:11 PM)

After market: 3.5 -0.03 (-0.85%)

3.53

+0.33 (+10.31%)



Find more stocks in the Stock Screener

Follow ChartMill for more